FDA IDENTIFIES NO NEW SAFETY CONCERNS ASSOCIATED WITH PROSTATE CANCER TREATMENT VACCINE SIPULEUCEL-T August 16, 2019 Sipuleucel-T was the first therapeutic vaccine approved by the U.S. Food and Drug Administration (FDA) in 2010. It is indicated for the treatment of asymptomatic or minimally symptomatic, metastatic, castration-resistant prostate cancer.This interview shares that no new safety concerns were identified with sipuleucel-T.Read the interview here.Source: Silvia Perez-Vilar Ph.D. - Medical Research Prostate Cancer News
Sipuleucel-T was the first therapeutic vaccine approved by the U.S. Food and Drug Administration (FDA) in 2010. It is indicated for the treatment of asymptomatic or minimally symptomatic, metastatic, castration-resistant prostate cancer.This interview shares that no new safety concerns were identified with sipuleucel-T.Read the interview here.Source: Silvia Perez-Vilar Ph.D. - Medical Research
Complete the Survey
